Unsaved Changes
You have unsaved changes, are you sure you want to leave this page?
Ann Arbor, Washtenaw County, Michigan
Asking Price
$2,000,000
Revenue
$893,000
Down
Call/Email
Cash Flow
$63,000
Name: Rick Carlson
Phone: Show phone number
Name
Rick Carlson
Phone
Show phone number
Year Established:
2005
Employees:
5
Reason for sale:
The Seller believes that he is best in the role of data scientist, not the CSO or CMO.
Support & Training:
The Seller is interested in maintaining a technical role within the company post-sale, potentially as a CTO, technical consultant, or board member, to continue contributing his expertise in developing advanced products, including AI-driven technologies.
Posting ID:
5560089
Attributes:
Financial Assistance
Training And Support
Recommended Businesses
Detroit, Michigan
Music Agency - Profitable, Increase of 600 Percent
$ 2,500,000
CF : $ 1,000,000
Our client is an exploding, music talent agency--yearly revenue has increased since inception, at a percentage rate year over year of approximately 600%. Our client is a 'positive hustle and hard work ethic' music talent business built on the sheer effort of bringing music artists to the performance stage. Built from the ground up, the business foundation has been developing emerging performance talent while using well-known artists to kick in larger revenue when possible. A great source of success has come from acquiring visas for in-demand international artists and bringing them to the US marketplace. Our client brings the following: - 80+ acts signed to exclusive contracts (1-to-2-year terms) - Robust artist scouting protocol signing on average 3 acts a week - Can be staffed with agents anywhere in the world - Access to the nation's largest contact book of venues, talent buyers, and promoters - Non-exclusive booking rights for Snoop Dogg, Ice Cube, OT Genasis, Xzibit, Warren G, Bizzy Bone, B.o.B, and Bone Thugs N Harmony - Over 1,000 performances booked in half of a calendar year (2022) - Artists in several genres are actively leaving their current booking agencies in favor of coming onto our client's roster. Our client has been awarded positive recognition by a large majority of its artists as well as publications like MoneyGeek, DMC World, Pollstar, Gigwell, and Shoutout Atlanta. The Company's key paradigm is to find and monetize talent. Our client's team is constantly scouting new talent locally and internationally and bringing them to the marketplace. Our client consults on all aspects of artist growth from graphic design and social media strategy to music guidance and consulting. Urgency drives the foundations and operations of Our client's enterprise. This has proven to be a successful strategy, as month over month, our client is showing exceptional growth: in 2022 up to July, the Company is averaging $86,500 per month in gross revenue. NDA is required to secure a comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Growth/Expansion: In CIM. Financing: Seller does not wish to finance. Support & Training: Provided at no charge to enable a smooth transition. Reason for Selling: other projects.
Chicago, Illinois
Clinical Stage Oncology Co. for Early Cancer Detection
Call/Email
CF : $ 1,091
The Company is a clinical-stage oncology company with a platform that combines biospectral impedance and AI/ML for point-of-care cancer detection. The lead product delivers rapid, in-procedure assessment of surgical margins—identifying the presence and location of cancer within minutes. Initial commercialization targets skin cancer, where the lead product can shorten procedures, spare healthy tissue, improve surgeon economics, and enhance outcomes. The Company has also built a compelling breast cancer dataset and plans to deploy the lead product to help dramatically reduce the ~20–25% re-surgery (re-excision) rate in partial mastectomies; the breast program is in line for non-dilutive CPRIT support. The Company has a collaboration with PHC Holdings (formerly Panasonic Healthcare; TSE:6529) to commercialize the lead product. The company anticipates FDA clearance in 2026 and profitability in 2028. Beyond skin and breast, the Company has generated promising data in lung, pancreatic, esophageal, and colon tissue. Follow-on products include a rapid biopsy-assessment device and a needle-based device leveraging the same platform. Use of Proceeds: This round will fund FDA clearance activities and the initial commercial launch of the lead product. NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.
Los Angeles, California
Gene And Cell Therapy Regulatory Consulting
Call/Email
CF : $ 1,144,000
Founded in 2011, the Company is a niche consulting and advisory firm serving in cell therapy, gene and gene-modified cell therapies, other regenerative medicines, tissue engineering, and cell-based drug discovery. The company's core focus is to improve cell & gene therapy innovations by providing consulting services for improving business strategy and achieving major regulatory milestones for companies. The Company has created a one-stop shop for all aspects of cell therapy and gene therapy, including quality checks, regulatory meetings, and submissions with the help of leading experts worldwide. The leadership has a unique combination of experience in the academic, biotech industry, government/FDA, and consulting. They serve biotech, pharma companies, consulting services for healthcare providers, subcontracts for other consulting firms, and contracts with government organizations, which enables them to have 6x+ growth in net income from 2019 2021, i.e., $179,000 to $1,095,000 with the help of 110+ customers served over the past six years. The Company's plan is to consummate a transaction with a supportive growth partner in order to accelerate the company's cell and gene therapy market growth by interacting with industry, academia, government, and other international stakeholders in cell & gene therapies and cell-based drug discovery. NDA is required to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: Has headquarters in US contractors operate nationwide / portable / buyer can be located worldwide. Competition: A few competitors in the space are in the field but the Company provides best in class services for its respective niche(s). Growth & Expansion: Continually grow and become more profitable with the help of experts that supports preclinical, clinical, and commercial advisory in the manufacturing, regulatory affairs, Quality/GxP, and M&A arenas. Financing: If the price and deal structure is right. Support & Training: Long term transition, Seller wishes to smooth the transition to maximize success with the Company post-closing and spearhead continued growth. Reason for Selling: Growth.
Los Angeles, California
Major Streaming TV Channel Already Deployed
Call/Email
CF : $ 2,498
Our client opportunity was developed and founded by two giants of the industry. One of the founders brings a thirty-year career with the New York Football Giants in various director and executive capacities. He founded and chaired the NFL Video Directors Executive Committee, has multi-Emmy winning shows, multiple Telly and Aurora awards, three Super Bowl rings, and was a technical innovator on the team that created instant replay. The other founder was head of programming at Disney Channel for eleven years where the channel won over 100 Emmy/Ace awards and grew profits 20% per year for 10 years. He co-founded Tennis Channel managing launch and operations, and has launched over 30 TV channels including streaming channel Players TV and 18 Short Movie Channels worldwide. Our client has secured distribution agreements with major streaming platforms including Roku, Apple TV, Amazon Fire TV, Samsung TV, Mobile Users (Apple iOS and Android OS), and All Web Applications. Our client currently offers 50 hours of programming to viewers and is available on 500,000,000 devices with active streaming capability. Our client’s opportunity is currently operating. It is an English-language Italian and Italian American focused streaming channel and media brand targeting 30 million Italian Americans and 160 million Italophiles in the U.S. Our client has soft launched as a proof of concept and is building viewership through this ubiquitous distribution platform. Programming inventory consists of 50 hours of current programming featuring original and acquired programs in categories of cooking, Italian American lifestyles, culture, travel, comedy, inspirational, and documentaries. BritBox, a comparable British programming streaming service, recently sold 50% to the BBC for $322 million yielding a $644 million valuation. Our client targets a significantly larger audience of approximately 200 million Italian Americans and Italophiles through AI advertising, sponsorship, and e-commerce integration. The owners have an ecommerce platform in development through which viewers can purchase select Italian exquisite products and services, travel opportunities and other products featured on the channel. NDA required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.
Irvine, California
Pharmaceutical Company - Targeting Drug Delivery
$ 20,000,000
Patented Universal Tumor-Targeting Drug Delivery Platform Co. This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company's ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company's ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to "universally" target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers. The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin. The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations. As the Company's platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI. The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); follwed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company's valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approx. 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support. NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners. Detailed Information Competition: Trying to improve existing therapies and develop novel approaches to hard to treat cancers. Growth & Expansion: Huge market potential. Financing: If the price and deal structure is right. Support & Training: Transition team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .
Albany, New York
HVAC/Plumbing Division of a Company for Sale
Call/Email
CF : $ 658,524
The Company is a diversified business with multiple divisions, but its HVAC/Plumbing division is the cornerstone of operations. This division has built a strong reputation in its regional market by delivering trusted residential services, including plumbing and HVAC system installations, water service and treatment, well pump solutions, and recurring seasonal winterization. Its reputation is reinforced by decades of reliable service to both permanent and seasonal homeowners, positioning the business as the go-to resource in the area. With EPA-certified technicians and dedicated office staff for dispatch and billing, the HVAC/Plumbing division combines technical expertise with responsive customer support, ensuring consistent service quality and long-standing client relationships. In addition, the Company operates hardware, parts, and equipment rental divisions, providing customers with a broad selection of tools, supplies, and repair solutions to complement its core service offerings. NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.
San Jose, California
Patented Iris Recognition Technology Firm
Call/Email
CF : $ 9,280
Our client is a world leader in iris recognition technology with a large production capacity based in USA. They are a multinational corporation with a robust track record of selling its best-selling, award winning technology products worldwide. Clients include the UN, the US Department of Homeland Security, US Navy, US Marine Corps, the governments of India the Philippines, Kenya, and in the private Sector Northrop Grumman, InCadence and numerous others. The company has and continues to develop an ever-increasing range of technical applications for its products in a very large and rapidly growing market. Applications range from numerous physical security applications to blockchain and cryptocurrency applications. This firm owns 28 patents (24 registered and 4 pending) for its proprietary "iris matching algorithm, iris recognition in bright outdoors under sunlight" technology and security technology. Our client also has world-leading iris recognition technology to crypto wallet, which dramatically improves the security and convenience of digital assets on blockchain. In addition to multiple patents, our client also owns 10 trademarks. Our client's iris recognition algorithm was evaluated as the world's best technology at IREX I of NIST in the USA, and its excellence has been proven. They are one of few companies to provide a complete solution including SW and HW from iris image scanner to matching SDK on server with the world's best technology. This business has global references for the National ID projects of the Indian and Philippine governments They achieved the No.1 market share, including UN-affiliated organizations such as UNHCR and WFP, and these markets are expanding worldwide. Our client's tech and related device is the only iris camera system satisfying MOSIP SBI 2.0 requirements for authentication (many countries are utilizing the MOSIP platform for their National ID systems). Our client's unique and powerful technologies are registered and protected by global patents, enabling stable business development and expansion. The company offers a total data infrastructure solution (large or small data requirements) for Web 3.0 (Web 3.0 is the approach for a new iteration of the World Wide Web which incorporates concepts such as decentralization, blockchain technologies, and token-based economics). Their technologies are based on Blockchain, IPFS, and distributed storage of private keys (IPFS is a distributed file system that seeks to connect all computing devices with the same system of files. This means data can be securely shared for Know Your Customer and Anti-Money Laundering (KYC and AML) needs. This meets information sharing protocols between service providers and will lead to a new and open data economy. The ramifications are complete security for Bank information, Financial Transaction Data, Driving Data, SNS Contents, Health Information, Government/Education Certification, Insurance Information in short data stemming from virtually any source. Confidential Information Memorandum (CIM) is available upon receipt of our short online NDA. Financing: If the price and deal structure is right. Support & Training: Provided at no charge to enable a smooth transition Reason for Selling: World-wide expansion
Los Angeles, California
Auto Fleet Tech Analytics Maintenance Data Company
$ 745,000
Confidential Information Memorandum (CIM) available upon receipt of our short online NDA. * It is estimated that the marketplace for connected cars and automobile data is will reach $400BN by 2030. * There are currently ~280MM registered automobiles in the US today with ~65MM of them being connected cars * The Company has created a process that while working with 3rd party Companies in the space and simultaneously creating a near proprietary technology is able to harness processes related to car data, thereby creating an opportunity for Companies looking to enter the aftermarket space for consumers and/or enterprises already in the automobile space, * Ideally this would be an add-on solution for any Company that is in the fleet-auto space, or looking to create an expansive and/or sweeping platform for the Consumer space NDA is required to secure comprehensive Confidential Information Memorandum (CIM). Detailed Information: Facilities: Home Based Competition: Few if any Growth & Expansion: Ample Financing: Depending on offer and structure may be acceptable minimal if any Support & Training: As needed. Reason for Selling: Existing opportunities
Recommended Blogs
How To Buy A Business
What is a micro business?
BizBen News
Advertising A Business For Sale: Best And Worst - Words, Phrases, Strategies
Deal And Escrow Issues
Qualifying Business Buyers: Top Business Broker Discusses Top Strategies
Business Broker Information
Should Owners Hire Agents To Sell Business Listings?
How To Buy A Business
Retiring Baby Boomers And Their Effect On California Small Business Sales
Business Valuation Issues
Recycling Services: 3 Businesses That Will Turn Old Stuff Into New Money
Buying A Business
Top 5 Industries Of The Future For Business Buyers Of Small Businesses
Deal And Escrow Issues
Selling A California Small Business? This Checklist Will Determine Your Success
Business Purchase Financing
6 Possible Untruths Told To Business Buyers When Buying A Small Business
BizBen News
How To Advertise A Business For Sale Without Revealing Too Much
Business Purchase Financing
Buying A Small Business With No Money Down! Is This Possible?
Buying A Business
Buying Janitorial Small Businesses: Tips For Business Buyers
Buying A Business
Buying An Employment Agency - Now May Be The Time
Buying A Business
Allocation Of The Purchase Price When Selling A California Small Business
Buying A Business
Why Do Laundromats Fail?
Buying A Business
Don't Buy A Laundry Business Without First Reading These Five Tips
Buying A Business
Janitorial Cleaning Services: 6 Considerations When Buying Janitorial Businesses
How To Sell A Business
Sellers: First Impressions Are Critical When Selling A Small Business
Business Valuation Issues
Interpreting Reported Earnings From Sellers
Deal And Escrow Issues
Seller Training - An Overview About This Provision